EPB41L4A‑AS1 promotes endothelial dysfunction in preeclampsia through the miR‑26a‑2‑3p/15‑LOX‑1/p38 MAPK axis
Year: 2026
Type: article
Abstract: Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by systemic endothelial dysfunction. Long non‑coding RNA EPB41L4A‑AS1 has been implicated in pregnancy‑related disorders, but its role in PE remains unclear. Our previous work demonstrated that downregulation of miR‑26a‑2‑3p promotes endothelial injury via activation of the 15‑lipoxygenase‑1 (15‑LOX‑1)/p38 mitogen‑activated protein kinase (p38 MAPK) pathway. In the present study, whether EPB41L4A‑AS1 contributes to PE pathogenesis by regulating this axis was investigated. EPB41L4A‑AS1 expression was significantly upregulated in placental tissues from patients with PE and negatively correlated with miR‑26a‑2‑3p levels. Functional experiments revealed that EPB41L4A‑AS1 overexpression suppressed miR‑26a‑2‑3p, activated the 15‑LOX‑1/p38 MAPK pathway and promoted endothelial dysfunction, effects that were partially reversed by miR‑26a‑2‑3p mimics. In an L‑NAME‑induced PE mouse model, EPB41L4A‑AS1 overexpression exacerbated hypertension, proteinuria, placental apoptosis and oxidative stress, whereas miR‑26a‑2‑3p agomir administration attenuated these effects. Mechanistically, luciferase reporter assays revealed no direct binding between EPB41L4A‑AS1 and miR‑26a‑2‑3p, suggesting an indirect regulatory mechanism. Collectively, these findings identify EPB41L4A‑AS1 as a critical upstream regulator of the miR‑26a‑2‑3p/15‑LOX‑1/p38 MAPK axis in PE and suggest that targeting this pathway may represent a potential therapeutic strategy.
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7236765557
